SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-027293
Filing Date
2024-02-26
Accepted
2024-02-26 07:58:51
Documents
14
Period of Report
2024-02-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm247177d1_8k.htm   iXBRL 8-K 24711
  Complete submission text file 0001104659-24-027293.txt   196223

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mrkr-20240222.xsd EX-101.SCH 3018
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrkr-20240222_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrkr-20240222_pre.xml EX-101.PRE 22361
15 EXTRACTED XBRL INSTANCE DOCUMENT tm247177d1_8k_htm.xml XML 3510
Mailing Address 4551 KENNEDY COMMERCE DR. HOUSTON TX 77032
Business Address 4551 KENNEDY COMMERCE DR. HOUSTON TX 77032 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

IRS No.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37939 | Film No.: 24673585
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)